Study on a noninvasive method for rapid screening Human Serum albumin injectables by Raman spectroscopy

Yu Zhao*, Nan Ji[†], Xiuji Li*, Jifeng Hou*, Min Li[‡], Yongjian Yang[‡],
Ping Tian[†], Xinmei Sun[†], Xinyue Xiao* and Lihui Yin^{*,§}

**National Institutes of Food and Drug Control (NIFDC)
No. 2 Tiantan Xi Li, Beijing, P. R. China*

*[†]Sichuan Vspec Technologies Co. Ltd. Beijing Office
No. 2 BeiTaiPingZhuang Road, Beijing, P. R. China*

*[‡]Shanghai Institute for Food and Drug Control (SIFDC)
No. 1500 Zhangheng Road, Shanghai, P. R. China
[§]yinlihui@vip.163.com*

Received 22 November 2015

Accepted 18 January 2016

Published 10 March 2016

Human serum albumin (HSA) injectable product is a severely afflicted area on drug safety due to its high price and restricted supply. Raman spectroscopy performances high specificity on HSA detection and it is even possible to determine HSA injectable products noninvasively. In this study, we developed a noninvasive rapid screening method for of HSA injectable products by using portable Raman spectrometer. Qualitative models were established by using principal component analysis combined with classical least squares (PCA-CLS) algorithm, while quantitative model was established by using partial least squares (PLS) algorithm. Model transfer in different instruments of both the same and different apparatus modules was further discussed in this paper. A total of 34 HSA injectable samples collected from markets were used for verification. The identification results showed 100% accuracy and the predicted concentrations of those identified as true HSA were consistent with their labeled concentrations. The quantitative results also indicated that model transfer was excellent in the same apparatus modules of Raman spectrometer at all concentration levels, and still good enough in the different apparatus modules although the relative standard deviation (RSD) value showed a little increasing trend at low HSA concentration level. In conclusion, the method was proved to be feasible and efficient for screening HSA injections, especially on its screening speed and the consideration of glass containers. Moreover, with inspiring results on the model transfer, the method could be used as a universal screening mean to different Raman instruments.

[§]Corresponding author.

This is an Open Access article published by World Scientific Publishing Company. It is distributed under the terms of the Creative Commons Attribution 4.0 (CC-BY) License. Further distribution of this work is permitted, provided the original work is properly cited.

Keywords: Human serum albumin; Raman noninvasive rapid screening method; principal component analysis combined with classical least squares; partial least squares; model transfer.

1. Introduction

- Human serum albumin (HSA) has acted as a pharmaceutical preparation for clinical use for more than 50 years. HSA injectables are protein preparations separated from the plasma of healthy humans. They are used to treat some extremely serious diseases in clinic, such as secondary shock and encephaledema caused by hemorrhage, burn or trauma, hydrops and ascites caused by liver cirrhosis or nephrosis, increased intracranial pressure caused by brain injury, hyperbilirubinemia of newborn, hypoproteinemia and so on.¹ Because the demand is great, but the supply is restricted, the price of HSA injectables is becoming extremely high, which motivated counterfeit criminals by large anticipated profits. In this case, a large number of fake and counterfeit incidents had been found in clinic and medicine trading market.² That has been endangering the public life safety. Therefore, HSA product is a severely afflicted area on drug safety and a more specific rapid screening method is badly in need especially on-site use.
- At present, there are many measurement methods for HSA determination,^{1,3–8} such as colorimetry, polarimetry, Kjeldah, ultraviolet (UV) spectroscopy, liquid chromatography (LC), liquid chromatography-mass spectrometry (LC-MS), capillary electrophoresis (CE) and Raman spectroscopy. Amongst these methods, the first four were broadly used, especially the molybdate colorimetry method,¹ which is the most widely-used rapid screening method for HSA detection. However, these methods do not have enough specificity for HSA. On the other hand, although the LC, LC-MS and CE methods are specific enough for HSA, the complicated operation and consumption of solvents limit these methods for field use. Raman method has both benefits of the highly specific on protein and easy-to-use, and is considered as an efficient means for determination of HSA.^{7,8} Moreover, with the development of hardware technique, Raman instruments are becoming more miniature and portable, which makes the application of Raman spectroscopy a

bright and broad future on the field test. In our present studies, we developed a noninvasive Raman method for detecting the liquid injectables without taking out the glass containers.^{9–11} However, these works were performed in the chemical drug injectables, whose active pharmaceutical ingredient (API) signals were strong enough for isolating and extracting data process. So it was a serious challenge to transplant that method to HSA injectable products.

- In order to realize rapid screening of HSA injectable products in a noninvasive way, we developed a convenient and effective method for portable Raman spectrometer. In this paper, two main problems were solved. One was whether the signal from HSA could be extracted from the mixed spectra and distinguished from other substances. The other was whether the model established could be directly applied on different end-users' instruments.

2. Materials and Methods

2.1. Samples

HSA standard substance was acquired from Sigma-Aldrich with the purity of 96%. Analytical purity reagents twain 80, pure water, sodium chloride injection and compound amino acid injection (18AA) were used as the negative reference. And human immunoglobulin (HI) injections and egg white were used as negative challenge protein samples. Both real and counterfeit HSA injections collected from markets were used for the verification.

2.2. Solution preparation

Twain 80 and egg white were prepared into water solution for negative challenges use. Three series HSA solutions were prepared for the quantitative model. The first series concentrations of 2.0%, 4.9%, 6.5%, 9.8%, 11.7%, 14.6%, 19.5% and 23.8% (w/v) were made by dissolving HSA standard substance with water. The second series concentrations of 5%, 9%, 13%, 17%, 21%, 23% and 25% (w/v) were made

by mixing two known concentration HSA injectables of 5% (w/v) and 25% (w/v), respectively. The last series concentrations of 4.8%, 5.8%, 7.1%, 8.7%, 10.7%, 13.1%, 16.0% and 19.5% (w/v) were made by diluting a known concentration HSA injectable sample of 19.5% (w/v). Each solution was contained in ampoules, vials and bottles respectively to simulate the actual determination process.

2.3. Apparatus and software

Totally five sets of portable Raman spectrometers, No. 197121 (Metage OPAL-2800, Metage Scientific, UK), Nos. 685001, 685002, 685004 (OPAL-3000, Metage Scientific, UK) and No. 140603308 (iRaman-plus, BWTEK, USA) were used for this study. All spectrometers were equipped with fiber optic probes and 785 nm diode laser excitation sources. A specially designed sample compartment was utilized to assure measurement under dark environment and samples in ampoule, vials or bottle were at the focus point of the probe. RFDI software (version 2.0, Sichuan Vspec Technologies Co. Ltd.) was used for both data collection and model building. First derivative pre-processing was applied during method development.

2.4. Raman spectra collections

Offset correction, x -axis correction and y -axis correction were done on each Raman spectrometer before collecting the spectra. Raman spectra were collected with the output power of 400 mW, a resolution of 4.5 cm^{-1} and total scan time of 100 s in the spectral range of 200–3000 cm^{-1} . HSA samples in their original containers (ampoules, vials or bottles) were positioned in the specially designed sample compartment and measured directly through the glass containers. The API reference standard water solutions prepared in ampoules, vials and bottles were measured as same as the samples. Water spectra were collected in 1 cm quartz cuvettes.

2.5. Data analysis

In order to monitor and control the differences between separate Raman instruments, standardization had been done based on the offset, x -axis and y -axis corrections. Four performance indexes — wavelength accuracy and precision, signal to noise

and relative intensity — were utilized to quantify the differences. Thus, the differences between instruments could be controlled to a relatively acceptable level by means of setting thresholds of the four indexes. The thresholds are adjusted according to experiences and experimental feedbacks.¹²

Principal component analysis combined with classical least squares (PCA-CLS) algorithm was utilized to fit the pure HSA signal extracting from the injectable mixed signals with glass packages for the noninvasive determination of HSA injections. The signals from the glass containers contributed over 90% to the noninvasive spectra and varied from different manufactures. In order to achieve the best results of fitting, PCA was done on a wide range of glass spectra before the CLS was performed.^{9–11} With the extracted HSA spectra, we could build the models for both identification and quantification. The identification was done by means of calculating correlation coefficients between the HSA spectra extracted from samples and the reference spectrum collected from the HSA standard solution. The nearer the correlation coefficient was to one, the more the HSA signals extracted from the injectable sample were similar to the reference. According to the market investigation, four kinds of substances — twain 80, pure water, sodium chloride injection and compound amino acid injection (18AA) — were chosen as the negative reference for both threshold setting and validation. A “positive or negative” identification result could be achieved by using the thresholds, where positive is for a HSA product and negative is not.

The quantification was performance based on the results of the identification. If the identification results of the injectables were positive, further work would be performed in the calculation of the concentration of the HSA. And the partial least squares (PLS) model for quantification was built by using the known concentration HSA samples prepared. The leave-one-out cross-validation was used to select optimal parameters and avoid over fitting. To achieve better fitting results and calculation accuracy, pretreatment method of vector normalization was utilized on the Raman spectra to eliminate the differences coming from the different measurement conditions on base of controlling the quantitative performance indexes of different instruments. The optimal parameters were evaluated by considering the coefficient of determination for calibration

(R^2) and root mean square error of calibration (RMSEC).

Finally, the HSA products collected from the market were used for the validation of the methods we built.

3. Results and Discussion

3.1. Signal extraction for identification

As mentioned in previous study,^{9–11} the signals from the glass containers contribute most in noninvasive Raman spectra. In the HSA injectable products, there are primarily three kinds of glass containers, ampoule, vial and bottle. In fact, the walls of big bottles are much thicker than that of ampoules, vials and small bottles, so the signals of HSA are relatively weaker when contained in these bottles. As shown in Fig. 1, the Raman spectra before extraction of the pure HSA water solution should have four peaks of 1654 cm^{-1} , 1449 cm^{-1} , 1341 cm^{-1} and 1003 cm^{-1} , consistent with that contained in ampoule with thin wall, but that of HSA samples contained in vial and big bottle with thick walls showed up only three peaks and one peak, respectively. It is obvious that HSA signals will be easier to be extracted when the products contained in ampoules than in vials and bottles. Generally, we

consider the wall-thickness from 1 to 3 mm as “thick wall”. On the other hand, the materials of glass are varied, which have strong Raman signals that could also influent the extraction for identification. Therefore, in order to achieve better results for the actual samples, we established two HSA injectable identification models, which could be chosen according to the thickness of containers (as shown in Table 1).

4. Verification of Identification Models

The investigation on the HSA in markets indicated that the fake HSA injectables were mainly twain 80, amino acids, sodium chloride injection and water for injection. In these counterfeit cases, twain 80 were the most similar on apparent characteristic and compound amino acids were the most similar on molecular structures. However, the Raman spectra of above substances had significant differences with that of HSA. Figure 2 showed the spectra of twain 80 water solution and compound amino acid injection comparing with HSA water solution. It could be seen from Fig. 2 that bands around 1656 cm^{-1} (amide band I), 1448 cm^{-1} (amide band II), 1346 cm^{-1} (amide band III) and peak 1003 cm^{-1} (phenyl in side chain) were considered as the

Fig. 1. The Raman spectra before extraction, where (a) is of the pure HSA water solution contained in quartz cuvettes, (b) is of the sample contained in ampoule, (c) is of the sample contained in vial and (d) is of the sample contained in big bottle with thick wall.

Table 1. Identification models and relative parameters according to the thickness of containers' wall.

Models	Thickness of containers' wall	Calibration range (cm ⁻¹)	Spectra pretreatment	Thresholds for identification
ID model 1	Thin (ampoules, vial or some small bottles)	1800–600	Baseline correction	0.95
ID model 2	Thick (most bottles)	1050–980	Baseline correction	0.9

Fig. 2. Characteristic bands and peak of HSA spectrum comparing with spectra of twain 80 water solution and compound amino acid injection (18AA).

characteristic bands of HSA to distinguish from other small molecular substances. Meantime, when we used these small molecular substances to verify our identification models, the results showed us that it is easy to distinguish them from the HSA according to the correlation coefficients. Those with correlation coefficients lower than 0.9 were considered as negative results while others with correlation coefficients higher than 0.9 or even 0.95 were considered as positive results. Table 2 showed the correlation coefficients output from the identification model for both negative challenges and positive testing results.

Despite the fact that present investigations have not found cases of using other protein to counterfeit HSA, a foreseeable negative challenges had been done on the models in this study by using HI and egg white. As Fig. 3 shown, bands around

1656 cm⁻¹ (amide band I), 1448 cm⁻¹ (amide band II), 1346 cm⁻¹ (amide band III) and peak 1003 cm⁻¹ (phenyl in side chain) were also considered as the characteristic bands of HSA to distinguish from another proteins. When verifying the models, the correlation coefficients of HI and egg white were lower than 0.9. Thus, both the spectra and models told significant differences between HSA and other protein molecules. Table 2 showed both the negative challenge and positive testing results of the potential counterfeit substances above.

Moreover, 32 known HSA injection samples collected from markets were additionally used for verification of the identification models. All these samples were identified by LC-MS method and had testing reports as reference. Two more HSA injectable samples marked “Real” but without testing reports were also determined. The models were

Table 2. Negative challenges and positive testing results on potential counterfeit substances.

Substances	Mean correlation coefficient	Repetition testing	Identification results
Twain 80	0.2783	6	negative
Single amino acid injection	0.5029	6	negative
Compound amino acid injection	0.4547	6	negative
Water for injection	−0.1754	6	negative
Sodium Chloride Injection	−0.2148	6	negative
Egg white	0.7836	6	negative
HI injection	0.8523	6	negative
HSA injection	0.9854	6	positive

Fig. 3. Characteristic bands and peak of HSA spectrum comparing with spectra of other protein molecules (HI water solution and egg white).

chosen according to the thickness of glass containers. Final positive or negative results were evaluated by comparing the correlation coefficients with thresholds of each model. As shown in Table 3, all the identification results were consistent with the reference.

5. Quantification and Model Transfer

The quantitative model was performed on the prepared HSA water solutions with known concentrations. With the pretreatment of vector normalization and spectra ranges of $3200\text{--}2500\text{ cm}^{-1}$ and $1146\text{--}800\text{ cm}^{-1}$, the PLS model produced an R^2 of 0.9911 in calibration. As shown

in Fig. 4, the cross-validation results performed well in linear with the corresponding minimum RMSECV value of 0.64.

Quantitative analysis should be based on the results of identification. Only samples that were identified as positive would go further for quantification. Samples No. 1–5 in Table 2 were used for the verification of the PLS model (Table 4). The predicted concentrations were on the same level of the labeled concentrations. As a screening method, requirements on quantification are more flexible compared with other analytical methods. In our screening method, only predicted concentration and labeled concentrations were provided as final results, without giving a conclusion of fake or

Table 3. Identification results of real and fake HSA injectatble products collected from the market.

No.	Labeled manufactures	Sample source	Batch no.	Labeled amount	Known Real/Fake	Chosen models	Correlation coefficient	Identification results
1	A	Shanghai	20060924	20%	Real	ID model 1	0.9718	positive
2	A		20060929	20%	Fake	ID model 1	0.3235	negative
3	B		20120835	20%	Real	ID model 1	0.9650	positive
4	C		200804030	10%	Real	ID model 1	0.9771	positive
5	D		VNA1J125	5%	Real	ID model 2	0.9634	positive
6	E	Nanning	201104113	20%	Fake	ID model 2	0.2154	negative
7	E		201203115	20%	Fake	ID model 2	0.2567	negative
8	F		201205115	20%	Fake	ID model 2	0.2291	negative
9	F		201302077	20%	Fake	ID model 2	0.2618	negative
10	G	Jilin	20060434	20%	Fake	ID model 1	0.3247	negative
11	G		20061144	20%	Fake	ID model 1	0.2844	negative
12	H		43644411A	20%	Fake	ID model 1	0.1903	negative
13	I		200606A026	20%	Fake	ID model 2	0.2220	negative
14	J		20060308	20%	Fake	ID model 1	0.4766	negative
15	I		200601003	20%	Fake	ID model 2	0.3389	negative
16	K		200609002	20%	Fake	ID model 1	0.2811	negative
17	J		20050924	20%	Fake	ID model 1	0.2994	negative
18	J		20060308	20%	Fake	ID model 1	0.4626	negative
19	G		20060434	20%	Fake	ID model 1	0.3829	negative
20	C		200602016	20%	Fake	ID model 1	0.3465	negative
21	L		200604019	20%	Fake	ID model 1	0.4363	negative
22	K		200609002	20%	Fake	ID model 1	0.2846	negative
23	L		200609042	20%	Fake	ID model 1	0.2848	negative
24	I		20050904A0	20%	Fake	ID model 2	0.2574	negative
25	I		20050905A0	20%	Fake	ID model 2	0.1575	negative
26	I		200512A063	20%	Fake	ID model 2	0.3664	negative
27	G		20061144	20%	Fake	ID model 1	0.2687	negative
28	I		200604A018	20%	Fake	ID model 2	0.4621	negative
29	I		200607A031	20%	Fake	ID model 2	0.2684	negative
30	H		32644411A	20%	Fake	ID model 1	0.5824	negative
31	H		436644411A	20%	Fake	ID model 1	0.4168	negative
32	A		20060924	20%	Fake	ID model 1	0.2586	negative
33	A	NIFDC	20060929	20%	marked "Real"	ID model 1	0.9537	positive
34	D		A250A6661	20%	marked "Real"	ID model 2	0.9621	positive

counterfeit. That is because the practical situation will be more complex than figures themselves.

Furthermore, a rapid screening method needs to be adaptable to a wide and varied range. So the models, we established should have to be transferred in different instruments instead of re-building the model each time measurement conditions changed. In this study, model transfer was researched in both the same apparatus modules and different apparatus modules. Instrument No. 685001 (Opal3000) was the one that the quantitative model being established on, and instruments No. 685002 and 685004 were utilized to validate the model transfer in different instruments of the same apparatus modules, while instruments No. 140603308

(iRaman-plus) and No. 197121 (Opal2800) were utilized to validate the model transfer in portable Raman spectrometers of different apparatus modules. As indicated in Table 4, the RSD values, on behalf of the model transfer results in the apparatus modules of Opal3000, were less than 1% at relatively high HSA concentration levels, while was 2.25% at a lower concentration level of 5%. As for different apparatus modules, the RSD value was 2% in higher concentration level and 6.17% at lower concentration level. These results indicated that model transfer was excellent in the same apparatus modules of Raman spectrometer at all concentration levels, while still good enough in the different apparatus modules although the RSD values

Fig. 4. Cross-validation results of the PLS model: (a) predicted concentrations vs actual concentrations; (b) minimum RMSWCV is 0.64 in the fourth rank.

showed a little increasing trend at low HSA concentration levels. This phenomenon is for the reason that sometimes signal-to-noise of spectra on low concentration level becomes worse due to the data-processing failure on glass containers, which will lead to a negative influence on the performance of quantification model. On this occasion, if this non-invasive way did not work on HSA concentration

lower than 5%, the way of taking HSA samples out of the glass containers could also be a wise choice. Moreover, as samples No. 33 and 34 were considered to be positive by the identification models, their concentrations were also predicted by the quantification model (as shown in Table 4) and the predicted concentrations were correspondent to labeled information as well.

Table 4. Verification results of quantification and model transfer.

Sample no.	Identification results	Labeled concentration/%	Predicted concentration/%	Raman instrument used	Model transfer in the same apparatus model RSD/%	Model transfer in different apparatus models RSD/%
1	positive	20	16.94	197121	—	1.24
			16.64	685001	0.24	
			16.56	685002		
			16.60	685004		
			16.37	140603308	—	
2	positive	20	19.46	197121	—	0.47
			19.54	685001	0.28	
			19.67	685002		
			19.58	685004		
			19.68	140603308	—	
4	positive	10	10.29	197121	—	1.13
			10.32	685001	0.92	
			10.41	685002		
			10.44	685004		
			10.59	140603308	—	
5	positive	5	5.72	197121	—	6.17
			6.87	685001	2.25	
			6.61	685002		
			6.32	685004		
			6.45	140603308	—	
33	positive	25	23.36	685004	—	—
34	positive	20	18.9	685004	—	—

6. Conclusion

In conclusion, Raman is an ideal method for non-invasive screening of HSA injectable products. And the method was proved to be feasible and efficient for screening HSA injections, especially on its screening speed and the consideration of glass containers. Moreover, with inspiring results on the model transfer, the method could be used as a universal screening means to different Raman spectrometers. And the possibility of on-site screening of HSA products will be of great significance on the drug-safety regulation.

Acknowledgments

This research was supported by Youth Development Research Foundation (No. 2015C03) of National Institutes of Food and Drug Control, P. R. China. The findings and conclusion of this paper have not been formally disseminated by the National Institutes of Food and Drug Control (NIFDC) and should not be construed to represent Agency determination or policy.

References

1. L. Xiao, Q. Shen, "Establishment and evaluation of rapid identification method of human albumin preparations," *China Pharmaceut. Affairs* **21**, 589–591 (2007).
2. Y. He, T. T. Ning, T. T. Xie, Q. C. Qiu, L. P. Zhang, Y. F. Sun, D. M. Jiang, K. Fu, F. Yin, W. J. Zhang, L. Shen, H. Wang, J. J. Li, Q. S. Lin, Y. X. Sun, H. Z. Li, Y. G. Zhu, D. C. Yang, "Large-scale production of functional human serum albumin from transgenic rice seeds," **108**, 19078–19083 (2011).
3. D. D. Rutstein, E. F. Ingenito, W. E. Reynolds, J. M. Burke, "The determination of albumin in human blood plasma and serum. A method based on the interaction of albumin with an anionic dye—2-(4'-hydroxybenzeneazo) benzoic acid," *J. Clin. Invest.* **33**, 211–221 (1954).
4. E. Domenici, C. Bertucci, P. Salvadori, G. Félix, I. Cahagne, S. Motellier, I. W. Wainer, "Synthesis and chromatographic properties of an HPLC chiral stationary phase based upon human serum albumin," *Chromatographia* **29**, 170–176 (1990).
5. M. Girard, A. Puerta, J. Carlos, M. D. Frutos, "High resolution separation methods for the determination of intact human erythropoiesis stimulating agents. A review," *Anal. Chim. Acta* **713**, 7–22 (2012).
6. M. Girard, H. P. Bietlot, N. Mousseau, T. D. Cyr, J.-C. Ethier, "Use of capillary electrophoresis for the characterization of human serum albumin heterogeneity," *Biomed. Chromatogr.* **12**, 183–184 (1998).
7. Y. Wang, S. H. Wang, J. G. Chen, "Rapid identification of human albumin injections by Raman spectroscopy," *Chin. J. Pharm. Anal.* **32**, 537–540 (2012).
8. D. Z. Mao, X. X. Wang, Y. J. Yang, "Determination of Human Albumin by Raman spectroscopy," *Chin. J. Pharmaceut.* **43**, 776–779 (2012).
9. Y. Zhao, N. Ji, L. H. Yin, J. Wang, "A non-invasive method for the determination of liquid injectables by Raman spectroscopy," *AAPS Pharm. Sci. Tech.* **16**, 914–921 (2015).
10. Y. Zhao, N. Ji, L. H. Yin, L. Zhu, X. B. Zhang, "Establishment of a Raman database for non-invasive and rapid screening of liquid injectables," *Chin. J. Pharm. Anal.* **35**, 1263–1273 (2015).
11. L. H. Yin, Y. Zhao, N. Ji, J. Wang, Y. J. Gao, X. B. Zhang, L. Zhu, "A method for determination of liquid injectables by Raman spectroscopy," Patent of invention, ZL201210593760.9, China (2015).
12. Y. Zhao, L. H. Yin, N. Ji, Y. J. Gao, J. Wang, L. Zhu, X. B. Zhang, "A method for eliminating the differences between Raman spectrometers," Patent of invention, ZL201310048251.2, China (2015).